Alvotech (ALVO) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alvotech, a global biotech firm, has issued over 22 million new ordinary shares to convertible bondholders at a fixed price of $10.00 each, a move that increases its total issued shares to approximately 324.8 million. This strategic step allows bondholders, primarily current shareholders, to convert their holdings before the bonds mature in December 2025, reflecting the company’s ongoing efforts to integrate and expand its biosimilar medicines market presence globally.
For further insights into ALVO stock, check out TipRanks’ Stock Analysis page.

